Saije K. Morosin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Saije K. Morosin has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Kirsty G. Pringle
Reproductive and Family Health Research Program, Hunter Medical Research Institute
5 shared publications Eugenie R. Lumbers
School of Biomedical Sciences and Pharmacy, College of Health Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia; Women's Health Research Program, Hunter Medical Research Institute, Newcastle, New South Wales, Australia
3 shared publications- Eugenie R. Lumbers
School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, Australia
2 shared publications Sarah J. Delforce
School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
2 shared publications- Cassandra Brennan
School of Biomedical Sciences and Pharmacy, College of Health Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
1 shared publication Celine Corbisier de Meaultsart
School of Biomedical Sciences and Pharmacy, Priority Research Centre for Reproductive Science, Pregnancy and Reproduction Program, Hunter Medical Research Institute, University of Newcastle, Newcastle, Australia
1 shared publication
Latest Publications
- Open Access
- 16 October 2025
- Published by Wiley in The Journal of Physiology
- Vol. 603 (22) , 7305-7321
Angiotensin‐converting enzyme 2 regulates the placental response to repeated hypoxia–reoxygenation insult
Fetal growth restriction is linked to placental oxidative stress owing to defective placentation and hypoxia–reoxygenation (H/R). Angiotensin‐converting enzyme 2 (ACE2), a key regulator of oxidative stress, is reduced in placentae of fetuses with growth restriction. We aimed to develop a physiologically relevant model of repeated H/R to determine the protective role of ACE2 during repeated H/R insult. Human term placental explants ( n = 8 per group) were cultured for 24 h in normoxia (8% O 2 ), non‐physiological H/R [6 h cycles of 1% (hypoxia chamber) and 8% O 2 (incubator)] or our novel physiological H/R model (6 h cycles of 1% and 8% O 2 in a single hypoxia chamber), with or without recombinant human (rh)ACE2. Physiological H/R, in contrast to non‐physiological H/R, decreased membrane‐bound ACE2 protein compared with normoxia. Physiological H/R also increased NADPH oxidase 5 ( NOX5 ) mRNA and protein, NOX4 protein and xanthine dehydrogenase ( XDH ) mRNA compared with normoxia. Physiological H/R increased levels of antioxidants superoxide dismutase 1 ( SOD1 ) mRNA, heme oxygenase 1 ( HO‐1 ) mRNA and protein, and glutathione reductase ( GSR ), nuclear factor erythroid 2‐related factor ( Nrf2 ) and NADPH quinone oxidoreductase 1 ( NQO1 ) mRNA above normoxia. Conversely, physiological H/R reduced SOD, CAT and GPx activity below normoxia. Non‐physiological H/R had no effect on ROS or antioxidant enzymes except for increasing GSR mRNA compared with normoxia. The rhACE2 reduced NOX5 mRNA and NOX4 and NOX5 protein and increased CAT and GPx activities compared with physiological H/R alone. Using a novel repeated H/R model, we show that repeated H/R downregulates ACE2 protein and induces placental oxidative stress, which can be mitigated by rhACE2 in vitro . image Key points: A physiologically relevant repeated hypoxia–reoxygenation (H/R) model was established using human placental explants that show upregulated NOX5, NOX4 and XDH, driving the generation of reactive oxygen species. Repeated H/R insult reduces membrane‐bound ACE2 protein, contributing to oxidative stress in placental tissue. The mRNA and protein levels of key antioxidants (SOD1, HO‐1, GSR, Nrf2 and NQO1) were elevated, but paradoxically, enzymatic activities (SOD, CAT and GPx) were reduced. Recombinant human ACE2 supplementation reversed oxidative markers and restored antioxidant enzyme activities, thereby mitigating H/R‐induced placental dysfunction. Our findings enhance understanding of placental oxidative regulation and offer new therapeutic direction for fetal growth restriction.
- 16 October 2025
- Published by Wiley in The Journal of Physiology
- Vol. 603 (22) , 7305-7321
Open AccessAngiotensin‐converting enzyme 2 regulates the placental response to repeated hypoxia–reoxygenation insult
Fetal growth restriction is linked to placental oxidative stress owing to defective placentation and hypoxia–reoxygenation (H/R). Angiotensin‐converting enzyme 2 (ACE2), a key regulator of oxidative stress, is reduced in placentae of fetuses with growth restriction. We aimed to develop a physiologically relevant model of repeated H/R to determine the protective role of ACE2 during repeated H/R insult. Human term placental explants ( n = 8 per group) were cultured for 24 h in normoxia (8% O 2 ), non‐physiological H/R [6 h cycles of 1% (hypoxia chamber) and 8% O 2 (incubator)] or our novel physiological H/R model (6 h cycles of 1% and 8% O 2 in a single hypoxia chamber), with or without recombinant human (rh)ACE2. Physiological H/R, in contrast to non‐physiological H/R, decreased membrane‐bound ACE2 protein compared with normoxia. Physiological H/R also increased NADPH oxidase 5 ( NOX5 ) mRNA and protein, NOX4 protein and xanthine dehydrogenase ( XDH ) mRNA compared with normoxia. Physiological H/R increased levels of antioxidants superoxide dismutase 1 ( SOD1 ) mRNA, heme oxygenase 1 ( HO‐1 ) mRNA and protein, and glutathione reductase ( GSR ), nuclear factor erythroid 2‐related factor ( Nrf2 ) and NADPH quinone oxidoreductase 1 ( NQO1 ) mRNA above normoxia. Conversely, physiological H/R reduced SOD, CAT and GPx activity below normoxia. Non‐physiological H/R had no effect on ROS or antioxidant enzymes except for increasing GSR mRNA compared with normoxia. The rhACE2 reduced NOX5 mRNA and NOX4 and NOX5 protein and increased CAT and GPx activities compared with physiological H/R alone. Using a novel repeated H/R model, we show that repeated H/R downregulates ACE2 protein and induces placental oxidative stress, which can be mitigated by rhACE2 in vitro . image Key points: A physiologically relevant repeated hypoxia–reoxygenation (H/R) model was established using human placental explants that show upregulated NOX5, NOX4 and XDH, driving the generation of reactive oxygen species. Repeated H/R insult reduces membrane‐bound ACE2 protein, contributing to oxidative stress in placental tissue. The mRNA and protein levels of key antioxidants (SOD1, HO‐1, GSR, Nrf2 and NQO1) were elevated, but paradoxically, enzymatic activities (SOD, CAT and GPx) were reduced. Recombinant human ACE2 supplementation reversed oxidative markers and restored antioxidant enzyme activities, thereby mitigating H/R‐induced placental dysfunction. Our findings enhance understanding of placental oxidative regulation and offer new therapeutic direction for fetal growth restriction.
- Open Access
- 21 November 2024
- Published by Elsevier in Pregnancy Hypertension
- Vol. 38, 101169
Soluble (pro)renin receptor (s(P)RR) levels in women carrying Aboriginal and/or Torres Strait Islander babies; the Gomeroi Gaaynggal study
- 21 November 2024
- Published by Elsevier in Pregnancy Hypertension
- Vol. 38, 101169
Open AccessSoluble (pro)renin receptor (s(P)RR) levels in women carrying Aboriginal and/or Torres Strait Islander babies; the Gomeroi Gaaynggal study
- 20 October 2021
- Published by American Physiological Society in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
- Vol. 321 (6) , R833-R843
ACE2: a key modulator of the renin-angiotensin system and pregnancy
Angiotensin-converting enzyme 2 (ACE2) is a membrane-bound protein containing 805 amino acids. ACE2 shows approximately 42% sequence similarity to somatic ACE but has different biochemical activities. The key role of ACE2 is to catalyze the vasoconstrictor peptide angiotensin (ANG) II to Ang-(1–7), thus regulating the two major counterbalancing pathways of the renin-angiotensin system (RAS). In this way, ACE2 plays a protective role in end-organ damage by protecting tissues from the proinflammatory actions of ANG II. The circulating RAS is activated in normal pregnancy and is essential for maintaining fluid and electrolyte homeostasis and blood pressure. Renin-angiotensin systems are also found in the conceptus. In this review, we summarize the current knowledge on the regulation and function of circulating and uteroplacental ACE2 in uncomplicated and complicated pregnancies, including those affected by preeclampsia and fetal growth restriction. Since ACE2 is the receptor for SARS-CoV-2, and COVID-19 in pregnancy is associated with more severe disease and increased risk of abnormal pregnancy outcomes, we also discuss the role of ACE2 in mediating some of these adverse consequences. We propose that dysregulation of ACE2 plays a critical role in the development of preeclampsia, fetal growth restriction, and COVID-19-associated pregnancy pathologies and suggest that human recombinant soluble ACE2 could be a novel therapeutic to treat and/or prevent these pregnancy complications.
- 20 October 2021
- Published by American Physiological Society in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
- Vol. 321 (6) , R833-R843
ACE2: a key modulator of the renin-angiotensin system and pregnancy
Angiotensin-converting enzyme 2 (ACE2) is a membrane-bound protein containing 805 amino acids. ACE2 shows approximately 42% sequence similarity to somatic ACE but has different biochemical activities. The key role of ACE2 is to catalyze the vasoconstrictor peptide angiotensin (ANG) II to Ang-(1–7), thus regulating the two major counterbalancing pathways of the renin-angiotensin system (RAS). In this way, ACE2 plays a protective role in end-organ damage by protecting tissues from the proinflammatory actions of ANG II. The circulating RAS is activated in normal pregnancy and is essential for maintaining fluid and electrolyte homeostasis and blood pressure. Renin-angiotensin systems are also found in the conceptus. In this review, we summarize the current knowledge on the regulation and function of circulating and uteroplacental ACE2 in uncomplicated and complicated pregnancies, including those affected by preeclampsia and fetal growth restriction. Since ACE2 is the receptor for SARS-CoV-2, and COVID-19 in pregnancy is associated with more severe disease and increased risk of abnormal pregnancy outcomes, we also discuss the role of ACE2 in mediating some of these adverse consequences. We propose that dysregulation of ACE2 plays a critical role in the development of preeclampsia, fetal growth restriction, and COVID-19-associated pregnancy pathologies and suggest that human recombinant soluble ACE2 could be a novel therapeutic to treat and/or prevent these pregnancy complications.
- Open Access
- 21 June 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (7) , 1-7
FURIN and placental syncytialisation: a cautionary tale
FURIN is a pro-protein convertase previously shown to be important for placental syncytialisation (Zhou et al. [1]), a process of cell fusion whereby placental cytotrophoblast cells fuse to form a multinucleated syncytium. This finding has been broadly accepted however, we have evidence suggesting the contrary. Spontaneously syncytialising term primary human trophoblast cells and BeWo choriocarcinoma cells were treated with either FURIN siRNA or negative control siRNA or the protease inhibitor, DEC-RVKR-CMK, or vehicle. Cells were then left to either spontaneously syncytialise (primary trophoblasts) or were induced to syncytialise with forskolin (BeWo). Effects on syncytialisation were measured by determining human chorionic gonadotrophin secretion and E-cadherin protein levels. We showed that FURIN is not important for syncytialisation in either cell type. However, in primary trophoblasts another protease also inhibited by DEC-RVKR-CMK, may be involved. Our results directly contrast with those published by Zhou et al. Zhou et al. however, used first trimester villous explants to study syncytialisation, and we used term primary trophoblasts. Therefore, we suggest that FURIN may be involved in syncytialisation of first trimester trophoblasts, but not term trophoblasts. What is more concerning is that our results using BeWo cells do not agree with their results, even though for the most part, we used the same experimental design. It is unclear why these experiments yielded different results, however we wanted to draw attention to simple differences in measuring syncytialisation or flaws in method reporting (including omission of cell line source and passage numbers, siRNA concentration and protein molecular weights) and choice of immunoblot loading controls, that could impact on experimental outcomes. Our study shows that careful reporting of methods by authors and thorough scrutiny by referees are vital. Furthermore, a universal benchmark for measuring syncytialisation is required so that various studies of syncytialisation can be validated.
- 21 June 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (7) , 1-7
Open AccessFURIN and placental syncytialisation: a cautionary tale
FURIN is a pro-protein convertase previously shown to be important for placental syncytialisation (Zhou et al. [1]), a process of cell fusion whereby placental cytotrophoblast cells fuse to form a multinucleated syncytium. This finding has been broadly accepted however, we have evidence suggesting the contrary. Spontaneously syncytialising term primary human trophoblast cells and BeWo choriocarcinoma cells were treated with either FURIN siRNA or negative control siRNA or the protease inhibitor, DEC-RVKR-CMK, or vehicle. Cells were then left to either spontaneously syncytialise (primary trophoblasts) or were induced to syncytialise with forskolin (BeWo). Effects on syncytialisation were measured by determining human chorionic gonadotrophin secretion and E-cadherin protein levels. We showed that FURIN is not important for syncytialisation in either cell type. However, in primary trophoblasts another protease also inhibited by DEC-RVKR-CMK, may be involved. Our results directly contrast with those published by Zhou et al. Zhou et al. however, used first trimester villous explants to study syncytialisation, and we used term primary trophoblasts. Therefore, we suggest that FURIN may be involved in syncytialisation of first trimester trophoblasts, but not term trophoblasts. What is more concerning is that our results using BeWo cells do not agree with their results, even though for the most part, we used the same experimental design. It is unclear why these experiments yielded different results, however we wanted to draw attention to simple differences in measuring syncytialisation or flaws in method reporting (including omission of cell line source and passage numbers, siRNA concentration and protein molecular weights) and choice of immunoblot loading controls, that could impact on experimental outcomes. Our study shows that careful reporting of methods by authors and thorough scrutiny by referees are vital. Furthermore, a universal benchmark for measuring syncytialisation is required so that various studies of syncytialisation can be validated.